What is Lonsurf (trifluridine/tipiracil) for?
Lonsurf (trifluridine/tipiracil) is a chemotherapy indicated for the treatment of people with advanced (metastatic) colorectal cancer who have been previously treated with chemotherapy and biological therapy1,2.
How does Lonsurf (trifluridine/tipiracil) work?
Lonsurf (trifluridine/tipiracil) is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells). It contains two active substances: trifluridine and tipiracil. In the body, trifluridine is converted into an active form that is incorporated directly into DNA, the genetic material of cells. As a result, trifluridine interferes with DNA function and prevents the cells from dividing and multiplying. The conversion of trifluridine into its active form occurs more readily in cancer cells than in normal cells, leading to higher levels of the active form of the medicine and a longer duration of action in cancer cells. This results in a reduced growth of cancer cells, while normal cells are only slightly affected. Tipiracil increases the level of trifluridine in the blood by slowing its breakdown. This, therefore, boosts trifluridine’s effect2.
Where has Lonsurf (trifluridine/tipiracil) been approved?
Lonsurf (trifluridine/tipiracil) was approved for previously treated advanced (metastatic) colorectal cancer by:
Food and Drug Administration (FDA), USA, September 22, 2015
European Medical Agency (EMA), European Union, April 25, 2016
Therapeutic Goods Administration (TGA), Australia, May 23, 2017
Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.
How is Lonsurf (trifluridine/tipiracil) taken?
The standard dosage is3,4,6:
Take trifluridine/tipiracil within 1 hour after completion of morning and evening meals.
Complete information about Lonsurf (trifluridine/tipiracil) dosage and administration can be found in the official prescribing information listed in our resources section3,4,6.
It is recommended that healthcare providers obtain complete blood counts prior to starting each treatment cycle of Lonsurf and monitor patients throughout treatment, as trifluridine/tipiracil may cause a severe decrease in blood cell and platelet production (myelosuppression)1,4.
Note: Please consult with your treating doctor for personalised dosing.
Are there any known adverse reactions or side effects of Lonsurf (trifluridine/ tipiracil)?
Common adverse reactions
The most common adverse reactions listed in the prescribing information include3,4,6:
Abnormal blood counts (anemia, neutropenia, thrombocytopenia)
asthenia/fatigue (lack of energy, tiredness)
Serious adverse reactions
The serious adverse reactions listed in the prescribing information include3,4,6:
bone marrow suppression (myelosuppression including anaemia, neutropenia,
leucopenia, and thrombocytopenia)
gastrointestinal toxicity (severe or persistent nausea, vomiting, diarrhoea, or abdominal pain)
Use in specific populations
As Lonsurf (trifluridine / tipiracil) can be fatal for a fetus, it is not advised for women who are pregnant or breast-feeding.
Avoid use in patients with moderate to severe hepatic impairment (liver dysfunction), and in patients with moderate renal impairment (kidney dysfunction)3,4,6.
For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information3,4,6.